Important Update for Biohaven Ltd. Investors
The Law Offices of Howard G. Smith is reaching out to investors regarding an important deadline. Those who have incurred losses from investing in Biohaven Ltd. (“Biohaven” or the “Company”) are encouraged to consider taking action before the upcoming deadline. Investors who acquired Biohaven securities during the specified Class Period may have recovery options available to them.
Understanding the Class Period
The relevant timeline for investors spans from March 24, 2023, to May 14, 2025. If you bought Biohaven securities during this time, you could be eligible to join the ongoing securities fraud lawsuit. This offers a crucial opportunity for investors to seek justice and potential compensation.
Contacting the Law Offices of Howard G. Smith
If you are one of the investors who suffered financial losses in Biohaven Ltd. (BHVN), the Law Offices of Howard G. Smith invites you to get in touch with them. Their team is prepared to assist you in understanding your rights and the next steps to take regarding the lawsuit.
Securities Fraud Allegations Against Biohaven
On July 17, 2023, Biohaven reported a significant setback when the FDA rejected their New Drug Application for the treatment of spinocerebellar ataxia (SCA), known as troriluzole. The rejection followed disappointing results from a Phase 3 trial that did not meet its primary endpoint. Following this announcement, Biohaven’s stock price plummeted by 22.6%, underscoring the impact of this negative news on investors.
The Sequence of Negative Developments
The situation worsened for Biohaven investors as further negative developments emerged. On March 3, 2025, the Company disclosed disappointing financial results related to its BHV-7000 treatment for bipolar mania, causing another significant drop in share price. Later, on April 25, 2025, reports circulated that Biohaven had withdrawn its Marketing Authorization Application for the same treatment, resulting in yet another decline in stock value. Finally, on May 14, 2025, news arrived that the FDA was extending the review period for the New Drug Application, which drove the stock down further.
Legal Implications and Class Action Details
The allegations in the ongoing lawsuit revolve around claims that Biohaven and its executives provided materially misleading statements about the viability of their treatments and the Company’s operations. Investors believed these misrepresentations, which ultimately led to significant losses when the facts became clear.
If you acquired Biohaven securities during this Class Period, you may have the right to file a motion with the Court to be appointed as lead plaintiff by the September 12, 2025, deadline.
Have Questions? Get in Touch!
If you’re interested in learning more about this class action lawsuit or if you have specific questions concerning your rights as a shareholder of Biohaven, please don’t hesitate to reach out to the Law Offices of Howard G. Smith:
- Law Offices of Howard G. Smith
- 3070 Bristol Pike, Suite 112
- Bensalem, Pennsylvania 19020
- Telephone: (215) 638-4847
- Email: howardsmith@howardsmithlaw.com
- Website: www.howardsmithlaw.com
Frequently Asked Questions
What is the class action lawsuit about?
This lawsuit claims that Biohaven Ltd. misled investors about its drug's regulatory prospects, leading to significant financial losses.
When is the deadline to join the lawsuit?
The critical deadline to file a motion to be a lead plaintiff is September 12, 2025.
How can I contact the Law Offices of Howard G. Smith?
You can reach them by phone at (215) 638-4847 or through email at howardsmith@howardsmithlaw.com.
Who is eligible to participate in the lawsuit?
Any investor who purchased Biohaven securities during the specified Class Period is eligible to participate in the lawsuit.
What should I do if I lost money investing in Biohaven Ltd.?
If you invested in Biohaven and lost money, it’s advisable to contact the Law Offices of Howard G. Smith to discuss your options regarding the ongoing lawsuit.
